Well, when you sell you don't usually hang around. I usually make a profit and leave. Sometimes it takes a while and sometimes it doesn't. Sometimes you cut your losses, but only a fool would pay $135 for a stock and ride it down to nothing. So you are either a liar or a fool in either case I would not pay much attention to you.
Looks like a supplier is gearing up for big demand. Demand driven by an expected good trial results?Looks like they don't expect it to take two more years either.
" Japan's Nissui bets big on fatty acids"
TOKYO A fatty acid found in the flesh of cold-water fish is believed to boost both brain function and cardiovascular health in humans. It may also be a key to the future fiscal health of Japan's Nippon Suisan Kaisha.
Nissui, as the company is known, is spending 8 billion yen ($72.4 million) on a new plant to produce eicosapentaenoic acid, or EPA, as it steps up investment outside its century-old mainstay seafood business. The company's share price has risen amid an aggressive restructuring effort that also includes cost-cutting and expanding in overseas markets including the U.S. and China.
The seafood company, Japan's second largest, reported record-high group net profit for the second straight year in the 12 months ended March. Its fisheries business posted 269.6 billion yen in sales, or 42% of the total. However, operating profit for the business fell 35.8% due to unfavorable market conditions.
The company's worst performer last year was its salmon and trout aquaculture business in Chile. Demand in Russia, a major consumer of the two fish, has dropped as the country's economy weakens amid international sanctions and declining oil prices. As a result, salmon and trout prices have fallen, forcing Nissui to log a valuation loss on the fish farm.
BETTING ON EPA "
So I would guess that would mean that other participants are down also. The first quarter is known to be a downer....Dah. But you always have an option to listen to Joe if you are inclined to pay attention to stupidity.
"$AMRN pump and dump. No volume. Authomatic trade. Pathetic pumpers. Terrible cash burn. Pathetic scripts. All ok in amrn s world"
Another demoralized, cry baby Short. Hahaha.
Amarin Corp. (NASDAQ: AMRN) was assumed with a Buy rating and a $3.50 price target (versus a $1.57 prior close) at Jefferies on May 12. The firm said it believes that the off-label Vascepa promotion in mixed dyslipidemia may be starting to bear fruit. It said:
We believe off-label Vascepa promotion in mixed dyslipidemia may be beginning to bear fruit, where our analysis of TRx data suggests a steeper upward trend in recent months v. 2015. Access to this population is a major source of upside, where we see opportunity of $2.5 billion. Focus is also on REDUCE-IT where we believe Vascepa can show a benefit on final analysis in early 2018, and upside could be $14 per share.
Amarin closed on Friday at $1.72. It has a consensus target price of $6.50 and a 52-week trading range "
Our system’s recommendation today is to STAY LONG. The previousBUY signal was issued on 05/16/2016, 4 days ago, when the stock price was 1.65. Since then AMRN has risen by +4.56%."